KRIBB Transfers Stem‑Cell Intestinal Organoid Therapy to Organoid Science in 8.3 Billion‑Won Deal

동아사이언스 reports a major transaction between KRIBB and Organoid Science. KRIBB is handing over its stem‑cell intestinal organoid therapy. The transfer is valued at 8.3 billion won. Organoid Science will assume development and commercialization responsibilities. The deal aims to accelerate therapeutic applications. Both parties expect the therapy to advance medical research. The agreement reflects growing investment in organoid technologies. Stakeholders will monitor progress toward clinical use.